FY2025 · ended Dec 31, 2025 · Revenue $18.67M, -29.3% YoY · Filed Mar 4, 2026
Omniab, Inc. (OABI) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $18.7 million and a net loss of $64.8 million. Free cash flow was -$37.0 million. As of Sep 30, 2026 it held $64.2 million in cash and investments and $18.1 million in total debt.
Revenue (TTM)
$40.21M
+90.6% vs year-ago TTM
Net income (TTM)
$-43.47M
+31.7% vs year-ago TTM
Operating cash flow (TTM)
$2.67M
+107.7% vs year-ago TTM
Free cash flow (TTM)
$2.38M
+106.8% vs year-ago TTM
EPS (TTM)
$-0.34
+42.7% vs year-ago TTM
Dividend per share
$2.50
Shares outstanding
144.78M
+18.5% vs prior year
Net cash
$46.07M
as of Sep 30, 2026
Operating margin
-115.9%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- OABI (Nasdaq), OABIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1846253
- Former names
- Avista Public Acquisition Corp. II (until Nov 1, 2022)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $18.7M | $26.4M | $34.2M | $59.1M | — |
| Operating income | -$69.0M | -$74.5M | -$69.4M | -$26.6M | — |
| Net income | -$64.8M | -$62.0M | -$50.6M | -$22.3M | -$27.0M |
| Diluted EPS | -$0.57 | -$0.61 | -$0.51 | -$0.26 | — |
| Operating cash flow | -$36.5M | -$39.7M | $2.3M | -$3.6M | -$5.7M |
| Free cash flow | -$37.0M | -$41.5M | $703,000 | -$20.8M | — |
| Total assets | $300.9M | $325.6M | $375.2M | $421.2M | $304.5M |
| Total liabilities | $33.9M | $37.9M | $60.6M | $79.8M | $70.2M |
| Stockholders' equity | $267.0M | $287.6M | $314.6M | $341.4M | $234.3M |
| Cash and investments | $54.0M | $59.4M | $87.0M | $88.3M | $0 |
| Total debt | $20.3M | $23.2M | $25.6M | $25.8M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 387 Omniab, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.